

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of :

Nils BRÜNNER et al.

Group Art Unit: To Be Assigned

Serial No.: 10/030,971

Examiner: To Be Assigned

Filed: January 15, 2002

For: COMPOSITION HAVING STEROIDAL ESTROGEN EFFECT WITHOUT
INCREASING THE RISK OF BREAST CANCER

INFORMATION DISCLOSURE STATEMENT

Under Secretary of Commerce for
Intellectual Property and Director of the
United States Patent and Trademark Office
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully
request consideration of the documents listed on the attached Form PTO-1449.

Copies of the documents listed are also enclosed.

Applicants respectfully request that the Examiner consider the documents
cited on the Form PTO-1449 and that the Examiner indicate that the documents
have been considered in this application by returning a copy of the Form PTO-1449
with the Examiner's initials in the left column per MPEP 609.

Applicants respectfully point out that the submission of the enclosed
documents in this IDS are not an admission that they are prior art or that they are
material to patentability of any claims of the application.

If any fees are incurred upon the filing of this Information Disclosure
Statement, including any petition fees, please charge the undersigned's Deposit
Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS

Date: May 16, 2002

By:

Stanislaus Aksman
Registration No. 28,562

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Telephone: (202) 955-1500
Facsimile: (202) 778-2201

RECEIVED
JUN 21 2002
TECH CENTER 1600/2900



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE

LIST OF MATERIALS CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:

60730.000002

SERIAL NO.:

10/030,971

INVENTOR'S NAME:

Nils BRÜNNER et al.

EXAMINER:

To Be Assigned

FILING DATE:

January 15, 2002


GROUP:

To Be Assigned

TECH CENTER 1600/2900

JUN 21 2002

RECEIVED



U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
A	6 2 6 7 9 9 4	07-31-01	Nesselhut et al.	424	773	08-14-98
B	5 5 6 5 1 9 9	10-15-96	Page et al.	424	195.1	02-07-95

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
C	EP 0 847 755 A1	06-17-98	Europe				X
D	AU 199748300 B2	06-18-98	Australia			X	
E	WO 98/26791	06-25-98	PCT			X Abstract	

OTHER MATERIALS (Including Author, Title, Date, Pertinent Pages, Etc.)

F	N. Beuscher, Salzgitter; <i>Cimicifuga racemosa</i> (<i>Cimicifuga racemosa</i> L. – Black Cohosh) L. – Die Traubensilberkerze ; 1995 ; Zeitschrift für Phytotherapie 16, 301-310; pp. 301-310, including English Language Abstract
G	N. Brünner, G.B. Bastert, H.S. Poulsen, M. Spang-Thomsen, S.A. Engelholm, L. Vindeløv, A. Nielsen, N. Tommerup and F. Elling; Characterization of the T61 Human Breast Carcinoma Established in Nude Mice*; 1985; Eur J Cancer Clin Oncol, Vol. 21, No. 7; pp. 833-843
H	Nils Brünner, Diane Bronzert, Lars L. Vindeløv, Kaare Rygaard, Mogens Spang-Thomsen and Marc E. Lippman; Effect on Growth and Cell Cycle Kinetics of Estradiol and Tamoxifen on MCF-7 Human Breast Cancer Cells Grown <i>in Vitro</i> and in Nude Mice; 03-15-89; Cancer Research 49; pp. 1515-1520
I	Nils Brünner, Claus Moser, Robert Clarke and Kevin Cullen; IGF-I and IGF-II expression in human breast cancer xenografts: Relationship to hormone independence; 1992; Breast Cancer Research and Treatment 22; pp. 39-45
J	Nils Brünner; C. Kent Osborne and Mogens Spang-Thomsen; Endocrine therapy of human breast cancer grown in nude mice; 1987; Breast Cancer Research and Treatment 10; pp. 220-242
K	N. Brünner, M. Spang-Thomsen, H. Skovgaard Poulsen, S.A. Engelholm, A. Nielsen and L. Vindeløv; Endocrine Sensitivity of the Receptor-Positive T61 Human Breast Carcinoma Serially Grown in Nude Mice; 1985; Int. J. Cancer: 35; pp. 59-64
L	Nils Brünner, Mogens Spang-Thomsen, Hans Skovgaard Poulsen, Lars L. Vindeløv and Svend Aage Engelholm; Characterization of the T60 Human Breast Carcinoma Grown in Nude Mice; 1985; Immune-Deficient Animals in Biomedical Research, 5 th Int. Workshop on Immune-Deficient Animals, Copenhagen 1985; pp. 234-241
M	N. Brünner, M. Spang-Thomsen, L. Vindeløv & A. Nielsen; Effect of 17 β -oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice; 02-15-83; Br. J. Cancer (1983), 47; pp. 641-647
N	N. Brünner, M. Spang-Thomsen, L. Vindeløv, A. Nielsen and S.A. Engelholm; Dose-Dependent Effect of 17 β -Estradiol Determined by Growth Curves and Flow Cytometric DNA Analysis of a Human Breast Carcinoma (T61) Grown in Nude Mice; 1985' Experimental Cell Biology; pp. 220-232
O	Nils Brünner, Mogens Spang-Thomsen, Lars Vindeløv, Jacob Wolffs and Svend Aage Engelholm; Effect of Tamoxifen on the Receptor-positive T61 and the Receptor-negative T60 Human Breast Carcinomas Grown in Nude Mice; Eur J. Cancer Clin Oncol. Vol. 21, No. 11; pp. 1349-1354; 1985
P	Nils Brünner, Birgit Svenstrup, Mogens Spang-Thomsen, Paul Bennett, Arne Nielsen and Jan Nielsen; Serum Steroid Levels in Intact and Endocrine Ablated Balb/c Nude Mice and Their Intact Littermates; 1986; J. steroid Biochem. Vol. 25, No. 3; pp. 429-432
Q	Eva-Maria Düker, Lothar Kopanski, Hubertus Jarry and Wolfgang Wuttke; Effects of Extracts from <i>Cimicifuga racemosa</i> on Gonadotropin Release in Menopausal Women and Ovariectomized Rats; Planta Med. 57 (1991); pp. 420-424

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 60730.000002	SERIAL NO.: 10/030,971
LIST OF MATERIALS CITED BY APPLICANT (Use several sheets if necessary)		INVENTOR'S NAME: Nils BRÜNNER et al.	EXAMINER: To Be Assigned
		FILING DATE: January 15, 2002	GROUP: To Be Assigned
	R	G. Harnischfeger and H. Stolze; Traubensilberkerze; 1980; Bewährte Wirksubstanzen aus Naturstoffen; notabene medici 1010 (1980); pp. 446-450	
	S	H. Jarry, Ch. Gorkow and W. Wuttke; Treatment of Menopausal Symptoms with Extracts of Cimicifuga Racemosa: <i>In vivo</i> and <i>in vitro</i> Evidence for Estrogenic Activity; Abteilung Klinische und Experimentelle Endokrinologie; pp. 99-112	
	T	Eckehard Liske, Eva Düker; Cimicifuga racemosa in Klinik und Forschung; ARS MEDICI 7/93; pp. 426-430	
	U	Pierre M. Martin, Kathryn B. Horwitz, Dale S. Ryan and William L. McGuire; Phytoestrogen Interaction with Estrogen Receptors in Human Breast Cancer Cells; 1978; Endocrinology Vol. 103, No. 5; pp. 1860-1867	
	V	Kåre Rygaard, M.D., D.Sci., and Mogens Spang-Thomsen, M.D., D.Sci.; Quantitation and Gompertzian analysis of tumor growth; 1997; Breast Cancer Research and Treatment 46; pp. 303-312	
	W	G. Warnecke; Beeinflussung klimakterischer Beschwerden durch ein Phytotherapeutikum; 1985; Die Medizinische Welt; medwelt, pp. 58/871-62/874	
	X	G. Vorberg; Therapie klimakterischer Beschwerden; 1984; ZFA Therapeutische Erfahrungen; Z. Allg. Med. 60; pp. 626-629	
	Y	Von G. Rauthe; Wechseljahresbeschwerden bei Mammakarzinompatientinnen; Fortschr. Med. 114. Jg. (1996) Nr. 5; pp. 26/46, 47/29, 30/48	
	Z	Shari Lieberman, Ph.D., C.N.S.; A Review of the Effectiveness of <i>Cimicifuga racemosa</i> (Black Cohosh) for the Symptoms of Menopause; 1998; Journal of Women's Health, Volume 7, Number 5; pp. 525-529	
	AA	Leena Hilakivi-Clarke, Elizabeth Cho, Ighovie Onojafe, Margarita Raygada and Robert Clarke; Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring; Oncology Reports 6; pp. 1089-1095; 1999	
	BB	Oncol Rep 1999 Sept-Oct; 6(5): 1089-95; Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis of female rat offspring	
	CC	Wei Sheng Yan Jiu 2001 Mar; 30(2): 77-80; [Estrogenicity of black cohosh (<i>Cimicifuga racemosa</i>) and its effect on estrogen receptor level in human breast cancer MCF-7 cells]	
	EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
 JUN 21 2002
 TECH CENTER 1600/2900